Posts tagged MRI
Paradigm starts Profound Medical at buy

Paradigm Capital launched coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2.25. The stock closed at 95 cents on Sept. 27.

Read More
GeneNews launches risk stratification test for breast cancer

GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).

Read More
Profound Medical sells first TULSA-PRO in Finland

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Read More
Echelon starts Profound Medical at buy

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.

Read More
Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13.

Read More
3D Signatures included in PRECISE prostate cancer trial

3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.

PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.

Read More
Roth downgrades iRadimed to neutral

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at $10.77 on Tuesday.

Analyst Chris Lewis writes that the announcement leaves him “incrementally cautious on the near-term pump growth profile and lengthening sales cycle.”

Read More
BTIG starts ViewRay at buy

BTIG Research launched coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and $6 price target. The stock closed at $3.58 on Tuesday.

MRIdian is the first commercial MRI guided radiation therapy treatment system available. “The image quality of the MRI is far superior to the imaging quality of the X-Ray and CT based systems today particularly with respect to soft-tissue cancers and anatomy,” writes analyst Dr. Sean Lavin.

Read More
Mackie starts Profound Medical at speculative buy

Mackie Research Capital initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and 12-month target price of $3.30. The stock was quoted at $1.45 at mid-day on Wednesday.

Read More
GMP starts Profound Medical at speculative buy

GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday.

The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side effects.

Read More